Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Sees Large Increase in Short Interest

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 184,900 shares, a growth of 88.1% from the February 13th total of 98,300 shares. Based on an average daily trading volume, of 79,200 shares, the short-interest ratio is presently 2.3 days. Approximately 10.8% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Creative Medical Technology stock. Geode Capital Management LLC acquired a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned approximately 0.59% of Creative Medical Technology as of its most recent SEC filing. Institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Trading Up 9.0 %

Shares of NASDAQ CELZ traded up $0.27 during trading hours on Friday, reaching $3.27. The stock had a trading volume of 155,245 shares, compared to its average volume of 37,064. Creative Medical Technology has a 52-week low of $1.96 and a 52-week high of $6.90. The firm has a market cap of $7.60 million, a price-to-earnings ratio of -0.86 and a beta of 1.70. The business’s fifty day moving average price is $3.71 and its two-hundred day moving average price is $3.28.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.